VistaGen Therapeutics Faces Class Action Lawsuit
Analysis based on 18 articles · First reported Jan 28, 2026 · Last updated Feb 11, 2026
The market is impacted by the significant decline in VistaGen Therapeutics' stock price, reflecting investor distrust due to the failed drug trial and subsequent class action lawsuit. This event highlights the risks associated with pharmaceutical development and the importance of transparent communication from publicly traded companies.
VistaGen Therapeutics is facing a class action lawsuit initiated by The Gross Law Firm on behalf of shareholders. The lawsuit alleges that VistaGen Therapeutics made materially false and misleading statements and/or concealed adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, a candidate for social anxiety disorder. On December 17, 2025, VistaGen Therapeutics announced that the trial did not demonstrate a statistically significant improvement on its primary endpoint, leading to an over 80% drop in its stock price from $4.36 to $0.86 per share. The class period for the lawsuit is from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard